All In Biotech

Drug Trial Radar · NCT07282210

Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension to Determine Efficacy and Safety of SIL-8301 in Sickle Cell Disease (SCD) Patients With a Predominantly Hemolytic Phenotype

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2029

Study completion Oct 2031

Sponsor

Lead sponsor
Biossil Inc.Industry
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as evidence of ongoing hemolysis and a baseline Hb of 9.5 g/dL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will take senicapoc or matching placebo daily and continue on hydroxyurea as prescribed for up to 24 weeks. Eligible participants that complete the 24 weeks will have an opportunity to receive senicapoc for up to 2 years in an optional open label extension.

Conditions

  • Sickle Cell Disease
  • Sickle Cell Anaemia
  • Sickle Cell Anemia

Interventions

  • SenicapocDrug

    10 mg tablets; administered at a loading dose of 20 mg twice daily for 4 days, followed by a maintenance dose of 10 mg once daily for up to 24 weeks

  • PlaceboDrug

    Tablets similar in size and color; matching administration schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hb response rateTime frame: 24 Weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Recruiting

  • University Health Network, Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.